These cells are responsible for making a crucial protein called intrinsic factor
Clinical and Research Safety Data BPC-157 safety: BPC-157 has been studied extensively with strong safety outcomes: No serious adverse events reported across thousands of research uses No organ toxicity observed in safety studies No hormonal or endocrine disruption No major drug interactions documented Well tolerated across diverse populations TB500 safety: TB500 similarly shows strong safety: Minimal adverse events in research studies No major toxicity in laboratory safety testing No hormonal disruption Good tolerability across many dosing protocols Safe in combination with other compounds Combined safety: The combination maintains the strong safety profile of both peptides: No combined toxicity when used together Adverse event rate remains very low No serious safety concerns identified Well tolerated across diverse research uses Common Side Effects (Mild and Transient) The most commonly reported side effects are minor and usually resolve quickly
Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, et al
In experimental wound healing models, TB-500 treatment increases capillary density by 40-50% while improving functional blood flow restoration, demonstrating translation of cellular angiogenic activity into meaningful tissue-level perfusion benefits
Annual cGMP certification Every year, without exception
